XUAB 2167 - A Phase II Circulating Tumor DNA Enriched, Gnomically Directed Post-Neoadjuvant Trial for Patients with Residual Triple Negative Breast Cancer (PERSEVERE): HCRN BRE18-334

Grant

Awarded By

Total Award Amount

  • 441100.00

    • Direct Costs

  • 324338.00

    • Sponsor Award Id

    • Contributor

  • Ahmed Elkhanany   Investigator  
  • Erica Stringer-Reasor M.D.   Principal Investigator  
  • Gabrielle Rocque M.D.   Investigator  
  • Katia Khoury   Investigator  
  • Lisle Nabell M.D.   Investigator